Edit |   |
---|---|
Antigenic Specificity | Apolipoprotein A1, APOA1 |
Clone | polyclonal |
Host Species | Mouse |
Reactive Species | human |
Isotype | n/a |
Format | Protein A purified |
Size | 0.1 mg |
Concentration | n/a |
Applications | Western Blot (WB) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Apolipoprotein A-I (APOA1) is the major protein component of high density lipoprotein (HDL) in plasma. [1] Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. [2]It was composed of an N-terminal 4-helix bundle with a hydrophobic core and 2 C-terminal helices. [3] It has an approximate molecular weight of 28 KDa. A G/A polymorphism in the promoter of the ApoA-I gene has been associated with the age at which patients presented with Alzheimer disease. [4] Protection from Alzheimer disease by ApoA1 may rely on a synergistic interaction with alpha-tocopherol. [5] |
Immunogen | Immunogen: A synthetic peptide (conjugated with KLH) corresponding to the region of human APOA1. |
Other Names | n/a |
Gene, Accession # | [APOA1], NCBI: CAA00975.1 |
Catalog # | MBS355173 |
Price | $275 |
Order / More Info | Apolipoprotein A1, APOA1 Antibody from MYBIOSOURCE INC. |
Product Specific References | 1. Breslow, J. L., Ross, D., McPherson, J., Williams, H., Kurnit, D., Nussbaum, A. L., Karathanasis, S. K., Zannis, V. I. Isolation and characterization of cDNA clones for human apolipoprotein A-I. Proc. Nat. Acad. Sci. 79: 6861-6865, 1982. 2. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ (january 2008). Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nature Reviews Drug Discovery 7 (1): 84-99. 3. Ajees, A. A., Anantharamaiah, G. M., Mishra, V. K., Hussain, M. M., Murthy, H. M. K. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc. Nat. Acad. Sci. 103: 2126-2131, 2006. 4. Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kolsch H (2005). APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann. Neurol. 58 (3): 436-41. 5. Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, Montine TJ, Montine KS (2004). Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J. Neurochem. 91 (6): 1312-21. |